Eli Lilly's oral GLP-1 receptor agonist Orforglipron showed significant weight loss, A1C reduction, and cardiometabolic ...

Michael Grosberg, vice president of product management, spoke with Pharmaceutical Executive about direct-to-consumer sales ...

Putnam’s CEO discusses advancements in oncology and how companies are working to ensure patients have access to these new ...

The collaboration provides BioArctic with an upfront payment of $30 million and potential milestone and royalty payments as ...

Genentech broke ground on a $700 million manufacturing facility in Holly Springs, North Carolina its first on the U.S. East ...

The acquisition adds Furoscix, an FDA-approved furosemide infusion therapy for chronic heart failure and kidney disease, ...

Derrick Gastineau, head of marketing at Currax Pharmaceuticals, spoke with Pharmaceutical Executive about the marketing landscape for weight loss medications and how it’s a therapeutic area where its ...

The CDC appointed Retsef Levi, a vocal critic of mRNA Covid-19 vaccines, to lead its Covid-19 immunization workgroup, a panel ...

Shiladitya Sengupta, founder, Vyome Therapeutics, explains how the company’s strong ties in India’s biotech and healthcare ...

New indication positions Repatha as an option for high-risk adults with elevated LDL cholesterol and no prior cardiovascular ...

Under terms of the deal, Gilgamesh could receive up to $1.2 billion as bretisilocin progresses through clinical development ...

BeOne Medicines entered a deal worth up to $950 million with Royalty Pharma selling its rights to global sales royalties of ...